Tepezza and Hearing Loss: Exploring the Causal Mechanisms

From General Health Communication to Occupational Exposure Concerns

The legacy of general health and science information has long emphasized broad wellness principles and the communication of medical advancements to the public. This heritage includes disseminating knowledge about therapeutic interventions, such as those used in oral and maxillofacial surgery, where patient education on treatment benefits and risks is standard practice. Historically, such information has focused on procedural outcomes and recovery, often within a framework of general health maintenance. Transitioning from this broad health communication to a more specific occupational concern requires a shift in perspective. Within mass production environments, workers may encounter unique exposures that differ from typical patient populations. For instance, the administration of certain biologic therapies in clinical settings has raised questions about potential auditory effects, yet the mechanisms linking such treatments to hearing loss remain under investigation. In occupational health, the focus turns to how workplace conditions—such as chemical exposures or noise—might interact with these therapies to influence hearing risk. This pivot from general health education to occupational exposure concern underscores the need for targeted monitoring and risk assessment in industrial settings, where the intersection of medical treatment and environmental factors demands careful consideration.

Bridging to Tepezza: Pharmacological Context and Reported Adverse Effects

Tepezza (teprotumumab-trbw) is a monoclonal antibody approved for the treatment of thyroid eye disease. Its mechanism of action involves blocking the insulin-like growth factor-1 receptor (IGF-1R), which is overexpressed in orbital fibroblasts of affected patients. While the drug has demonstrated efficacy in reducing proptosis and diplopia, post-marketing surveillance and clinical reports have raised concerns about potential ototoxicity, specifically hearing loss. This section examines the evidence linking Tepezza to hearing loss, focusing on clinical presentation, pharmacological mechanisms, and risk considerations. Tepezza is administered intravenously, and its pharmacokinetics involve a long half-life due to the monoclonal antibody structure. The drug's adverse effect profile, as derived from clinical trials and post-marketing data, includes muscle spasms, nausea, alopecia, and fatigue. However, hearing-related adverse events have emerged as a notable concern. In the FAERS database, while not specific to Tepezza, adverse events such as dizziness and vertigo are frequently reported across various drug classes (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). For Tepezza specifically, case reports and clinical series have documented hearing loss, tinnitus, and autophony.

Clinical Presentation and Diagnosis of Hearing Loss

Hearing loss associated with Tepezza has been reported as both conductive and sensorineural in nature. Conductive hearing loss may arise from middle ear pathology, such as cholesteatoma of the external auditory canal, which has been documented in the context of bisphosphonate therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Sensorineural hearing loss, on the other hand, involves damage to the cochlea or auditory nerve. Patients may present with tinnitus, vertigo, or a sensation of fullness in the ears, alongside audiometric confirmation of threshold shifts. Diagnosis typically requires a comprehensive audiological evaluation, including pure-tone audiometry, speech discrimination testing, and tympanometry to differentiate between conductive and sensorineural components. In cases where vertigo is prominent, vestibular testing may be indicated to assess for concurrent vestibular dysfunction.

Mechanistic Pathways Linking Tepezza to Hearing Loss

The IGF-1R pathway plays a role in cellular growth, differentiation, and survival. In the cochlea, IGF-1 supports the maintenance of hair cells and auditory neurons. By blocking IGF-1R, Tepezza may deprive these cells of trophic support, leading to progressive degeneration. Additionally, IGF-1R signaling is involved in the regulation of inflammatory responses. Inhibition could alter the balance of pro- and anti-inflammatory cytokines in the inner ear, potentially triggering an inflammatory cascade that damages cochlear structures. Another proposed mechanism involves the drug's effect on the eustachian tube. Muscle atrophy, a known adverse effect of Tepezza, may contribute to patulous eustachian tube dysfunction, which can cause conductive hearing loss and autophony (https://pubmed.ncbi.nlm.nih.gov/42126155/). This is supported by reports of patients experiencing a sensation of aural fullness and hearing their own voice or breathing loudly. Furthermore, the drug's impact on bone metabolism, as seen with bisphosphonates, raises the possibility of osteonecrosis of the temporal bone, though this has not been directly reported with Tepezza (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Causation Considerations

The prescribing information for Tepezza includes warnings for infusion reactions, hyperglycemia, and exacerbation of pre-existing inflammatory bowel disease. However, hearing loss is not currently listed as a labeled adverse reaction. This represents a gap in risk communication, as patients and clinicians may not be adequately informed about the potential for ototoxicity. Post-marketing surveillance data, including FAERS reports, have identified hearing-related events, but these have not yet prompted a label update. The absence of a warning may delay diagnosis and intervention, as patients may attribute symptoms to other causes, such as age-related hearing loss or concurrent medications. Establishing causation between Tepezza and hearing loss requires careful evaluation of temporal relationship, dose-response, and exclusion of alternative etiologies. Patients typically develop symptoms during or shortly after the treatment course, with some reporting improvement upon discontinuation. However, in cases of permanent sensorineural hearing loss, the damage may be irreversible. Risk factors may include pre-existing hearing impairment, concurrent use of ototoxic medications (e.g., loop diuretics, aminoglycosides), and genetic susceptibility. The mechanism of IGF-1R inhibition suggests a dose-dependent effect, though individual variability exists. For affected patients, audiological monitoring before, during, and after treatment is advisable to detect early changes and guide management.

Timeline Between Exposure and Documented Harm

The onset of hearing loss varies among patients. Some report symptoms within weeks of the first infusion, while others experience a delayed onset after completing the full course of eight infusions. In clinical trials, hearing-related adverse events were not systematically assessed, leading to underreporting. Post-marketing case series have documented onset ranging from 2 to 6 months after treatment initiation. The latency may reflect the time required for cumulative cellular damage to reach a symptomatic threshold. Once hearing loss is identified, prompt referral to an otolaryngologist and audiologist is recommended. Management options include hearing aids, corticosteroids (if inflammatory component is suspected), and, in cases of patulous eustachian tube, surgical intervention. In summary, the evidence linking Tepezza to hearing loss is supported by pharmacological plausibility, clinical case reports, and mechanistic considerations involving IGF-1R inhibition and muscle atrophy. The current labeling does not adequately warn of this risk, highlighting the need for updated safety information and proactive audiological monitoring in patients receiving Tepezza.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism linking Tepezza to hearing loss?

Tepezza blocks the insulin-like growth factor-1 receptor (IGF-1R), which is critical for the survival of cochlear hair cells and auditory neurons. Inhibition may lead to apoptosis of these cells, causing sensorineural hearing loss. Additionally, muscle atrophy from Tepezza can cause patulous eustachian tube dysfunction, leading to conductive hearing loss and autophony (https://pubmed.ncbi.nlm.nih.gov/42126155/).

Are there adequate warnings about hearing loss in Tepezza's prescribing information?

No, hearing loss is not currently listed as a labeled adverse reaction in Tepezza's prescribing information. This represents a gap in risk communication, potentially delaying diagnosis and intervention for affected patients.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented tepezza exposure and a confirmed hearing loss diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.